Conatus Pharmaceuticals Inc. (CNAT)

[Inoviorulez]

Besides Gilead the only other player in Liver Cirhossis is Galectin Therapeutics (GALT). GALT just posted a few months ago bad results for NASH Fibrosis. But GALT has a LC program going as well, but considering it did terrible in NASH Fibrosis I don't think GALT will do well with Liver Cirhossis. Other than Gilead and GALT that leaves Conatus. I am going to buy a 5,000 share position soon just waiting for a nice entry point to see how far it drops. Then I will hold till the results or potential partnership news.

I see that the NASH space is huge and Allergan paying $1.7 billion for TBRA really caught my attention. Especially since TBRA failed on the primary endpoint of study, but did well in the fibrosis score -- although FDA says that is now an approvable endpoint. Which is why Allergan bought Tobira. But if Conatus works in Liver Cirhossis that could be a bigger market as there are no treatments for that. NASH fibrosis will have some competitors like Intercept Pharmaceuticals, and Tobira.